Afoxolaner Powder

Physical state and appearance characteristics:
Afoxolaner powder appears as white to off white crystalline powder under standard conditions, which makes it easy to mix with other excipients in formulation development. Its crystal morphology may be further characterized by X-ray diffraction (XRD) to determine crystal stability. In the production of formulations, the particle size distribution of powders needs to be strictly controlled to ensure the uniform dispersion of drugs in chewable tablets. For example, NexGard chewable tablets are made into light red to reddish brown circular or square tablets using a specific process to ensure drug stability and enhance palatability.

Solubility and solvent selectivity:
The water solubility of Aflana is extremely low, with a solubility of only 3.4 × 10 ⁻⁵ g/L at 25 ℃, which limits the development of its water-based formulations. However, it exhibits good solubility in organic solvents, especially in dimethyl sulfoxide (DMSO) where the solubility can reach ≥ 250 mg/mL (399.44 mM). This characteristic provides convenience for laboratory research, for example, in pharmacokinetic experiments, DMSO is often used as a solvent to prepare stock solutions. In addition, further research is needed on the solubility in solvents such as ethanol and acetone to optimize the formulation process.

Thermal stability and storage conditions:
The thermal stability study of Aflana shows that it can maintain chemical stability for a long time at room temperature, but degradation may occur under high temperature or light conditions. Therefore, it is recommended to store at -20 ℃ or 2-8 ℃ in the dark to prevent loss of active ingredients. In the stability test of the formulation, it is necessary to monitor the changes in its content at different temperatures (such as 40 ℃/75% RH accelerated test) to ensure the quality of the product within its shelf life. For example, the expiration date of Nicosin chewable tablets is 24 months, and its sealed packaging design can effectively isolate moisture and oxygen, extending drug stability.

PH and pKa values:
The acidity coefficient (pKa) of Aflana is 12.45 ± 0.46 (predicted value), indicating that it exists in anionic form under physiological pH conditions. This characteristic affects its absorption mechanism in the gastrointestinal tract, for example, in dogs, Aflana enters the bloodstream through passive diffusion and carrier mediated transport. Its high pKa value also explains its stability in acidic environments (such as gastric juice), but ionization may occur under alkaline conditions, and the use of pH regulators needs to be considered in formulation design.

Spectral characteristics and identification methods:
The InChIKey of Afrana is OXDDDHGGRFRLEE-UFFAOYSA-N, and the SMILES code is C1(C(NCC(=O)NCC(F)(F)F)=O)=C2C(C=CC=C2)=C(C2CC(C3=CC(C(F)(F)F)=CC(Cl)=C3)(C(F)(F)F)ON=2)C=C1. These unique identifiers can be used for database retrieval and structure validation. Its UV visible absorption spectrum has characteristic absorption peaks at specific wavelengths, which can be used for content determination. For example, high-performance liquid chromatography (HPLC) is commonly used to detect purity (≥ 98%) and ensure the quality of raw materials.

Physical properties related to the formulation:
In formulation development, the physical properties of Aflana directly affect process parameters. For example, its high melting point requires temperature and pressure control during the compression process to avoid crystal transformation. The flowability of its powder needs to be improved by adding flow aids (such as microcrystalline cellulose) to ensure that the weight difference of the tablets meets pharmacopoeia standards. In addition, studies on the compatibility of Afurana with excipients have shown that it does not interact with commonly used excipients such as starch and lactose, but should avoid contact with metal ions to prevent catalytic degradation.

The correlation between physical properties and pharmacological effects:
The physical properties of afoxolaner powder are closely related to its pharmacological effects. For example, its low water solubility may lead to slow release in the gastrointestinal tract, prolonging the duration of drug efficacy (such as the monthly efficacy of Nissin). Its crystal morphology affects the dissolution rate, which in turn affects the peak time of blood drug concentration (Tmax=2-4 hours). In addition, its binding affinity with GABA receptors and glutamate gated chloride ion channels may be influenced by molecular conformation, and conformational stability is related to its physical state.